• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA approves OTC Nexium

News
Article

FDA has approved non-prescription esomeprazole 20mg (Nexium 24HR, Pfizer).

FDA has approved over-the-counter (OTC) esomeprazole 20mg (Nexium 24HR, Pfizer).

Pfizer acquired exclusive global rights from AstraZeneca in 2012 to market non-prescription Nexium, a popular medication for people suffering frequent heartburn.

“Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health, and is an important strategy for Pfizer,” said Paul Sturman, president, Pfizer Consumer Healthcare. “The FDA approval of Nexium 24HR is a significant milestone in executing against our plan.”

In 2013 global sales of Nexium reached $7.8 billion and was ranked number 6th in sales volume worldwide, according to IMS Health MIDAS (December 2013).

Sturman said the non-prescription Nexium will be available in the United States this year.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.